Hypercholesterolemia
Conditions
Keywords
Elevated low-density lipoprotein cholesterol, Inclisiran, Real-world
Brief summary
This was a single-center, retrospective, observational study (non-interventional study with secondary use of data) among patients in a real-world setting. This study used the medical record data from patients in Yiling. Eligible patients who newly initiated inclisiran from 26 January 2022 to 21 August 2023 were included. The retrospective data up to the date of ethics committee approval (April 2024) was collected. The study team collected patient data using an electronic case report form (eCRF) from April 2024 to June 2024.
Interventions
None listed
Sponsors
Novartis
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Received at least one inclisiran injection during the indexing period. * Had at least 9 months of follow-up from the index date (had at least one LDL-C assessment during baseline period and at least one LDL-C assessment at 9 months or later). * Patients signed the informed consent form.
Exclusion criteria
• Participated in any blinded interventional clinical studies anytime during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage Change From Baseline to Month 9 in Low Density Lipoprotein Cholesterol (LDL-C) Levels | Baseline, Month 9 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Month 9 in Total Cholesterol Levels | Baseline, Month 9 | — |
| Change From Baseline to Month 9 in Apolipoprotein B Levels | Baseline, Month 9 | — |
| Change From Baseline to Month 9 in non-High Density Lipoprotein Cholesterol Levels | Baseline, Month 9 | — |
| Change From Baseline to Month 9 in Serum Apolipoprotein A1 Levels | Baseline, Month 9 | — |
| Change From Baseline to Month 9 in High Density Lipoprotein Cholesterol Levels | Baseline, Month 9 | — |
| Change From Baseline to Month 9 in Lipoprotein (a) Levels | Baseline, Month 9 | — |
| Change From Baseline to Month 9 in Triglyceride Levels | Baseline, Month 9 | — |
| Absolute Change From Baseline to Month 9 in Low Density Lipoprotein Cholesterol (LDL-C) Levels | Baseline, Month 9 | — |
| Number of Patients who Switched at Least Once From Inclisiran to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Monoclonal Antibody Treatment | Up to 27 months | — |
| Number of Patients With Changes in Lipid-lowering Therapies (LLTs) | Up to 27 months | Changes in LLTs included: * LLT dose modification (dose increase, dose decrease). * LLT switches. * Use of new add-on therapy. * LLT interruption. * LLT discontinuation. * Time between first inclisiran injection and subsequent doses. |
| Proportion of Days Covered (Adherence) of Inclisiran Over 12 Months | 12 months | Proportion of Days Covered of inclisiran over 12 months was calculated by the days covered by inclisiran within 12 months divided by 12 months. |
| Number of Patients per Demographic Category | Baseline | Demographic categories included: * Age * Gender * Ethnicity * Smoking history * Alcohol use history |
| Number of Patients per Clinical Characteristic Category | Baseline | Clinical characteristics included: * Family history of hereditary disease * Comorbidities * Medication history * Concomitant medications and/or therapies * Background LLT regimens |
| Baseline Lipid Levels | Baseline | Lipids included, but were not limited to, LDL-C, total cholesterol, apolipoprotein B, non-high density lipoprotein cholesterol, serum apolipoprotein A1, high density lipoprotein cholesterol, lipoprotein (a), and triglycerides. |
| Number of Patients With at Least two Doses of Inclisiran After the First Injection of Inclisiran | Up to 27 months | — |
Countries
United States
Outcome results
None listed